Victoria, Australia-based StarPharma (OTCQX:SPHRY), seller of a lineup of women’s health products under the VivaGel brand, says the active ingredient, SPL7013, showed “significant activity”
against SARS-CoV-2 in lab studies, subsequently validated by replicate
testing against Gilead Sciences’ remdesivir (served as a positive
control).
The company believes it can fast track development
of SPL7013 for COVID-19 since it is already on the market in Europe,
Canada, Japan, Australia and Southeast Asia.
https://seekingalpha.com/news/3561304-starpharma-to-develop-covidminus-19-treatment
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.